title: HLA-B*5701 frequency in Chilean HIV-infected patients and in general population.
abstract: It has been demonstrated that HLA-B*5701 screening reduces the risk for hypersensitivity reaction to abacavir in HIV-infected patients. Since B*5701 prevalence varies among different populations, it is important to determine the carrier frequency prior to its use for the screening of HIV-infected patients.The aim of this study was to determine HLA-B*5701 carrier frequency in Chilean general population and HIV-infected patients referred for B*5701 typing. For that purpose 300 blood bank donors and 492 abacavir-naïve HIV-infected patients from Chile were screened for B*5701 by a sequence specific primer PCR.We detected 14/300 (4.7%) B*57-positive individuals in the Chilean general population, 11 (3.7%) were B*5701 positive, and 3 (1%) had another subtype.All were heterozygous,thus a B*5701 allele frequency of 2% was determined.Eleven of 492 (2.2 %) HIV-patients carried a B*5701 allele. The difference between these frequencies is probably due to slow progression of HIV infection in HLA-B*5701 carriers, thus less patients would require antiretroviral therapy and B*5701 typing. Considering the usefulness of B*5701 screening, its prevalence in the Chilean general population,and the availability of a validated method,we conclude that HLA-B*5701 typing in Chilean HIV-infected patients about to initiate abacavir treatment is strongly recommended.
authors.affiliation: Department of Clinical Laboratories, Pontificia Universidad Católica de Chile, Santiago, Chile. hpoggi@med.puc.cl
authors.forename: Helena
authors.initials: H
authors.lastname: Poggi
authors.forename: Alejandra
authors.initials: A
authors.lastname: Vera
authors.forename: Marcela
authors.initials: M
authors.lastname: Lagos
authors.forename: Sandra
authors.initials: S
authors.lastname: Solari
authors.forename: Luis
authors.initials: L
authors.lastname: Rodríguez P
authors.forename: Carlos M
authors.initials: CM
authors.lastname: Pérez
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002677:Chile; D015224:Dideoxynucleosides / Q000009:adverse effects* / Q000627:therapeutic use; D004342:Drug Hypersensitivity / Q000235:genetics*; D005787:Gene Frequency; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy*; D015235:HLA-B Antigens / Q000032:analysis* / Q000235:genetics; D006801:Humans; D016133:Polymerase Chain Reaction; D015995:Prevalence; D011446:Prospective Studies; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D015235:HLA-B Antigens; D000099227:Abacavir; C484830:HLA-B*57:01 antigen